Exelixis, Inc. ( NASDAQ:EXEL ) recently posted some strong earnings, and the market responded positively. We did ...

Cancer drug specialist Exelixis (NASDAQ: EXEL) was quite the stock market star on Friday. Following news that it's making a ...

Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma ...

Newly published detailed clinical trial data show why Exelixis abandoned a plan to seek an FDA approval for a combination of ...

Exelixis reported increased revenue and earnings in Q4 2024, driven by strong cabozantinib sales, though competitive ...

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a growth stock that ...

Exelixis (EXEL) announced final results from the phase 3 CheckMate -9ER pivotal trial evaluating Cabometyx in combination with Opdivo versus ...

Exelixis reported $515.2M in net product revenues in Q4'24, a 20% increase over net product revenues for Q4'23. See why I ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the Citi 2025 ...

TD Cowen raised the firm’s price target on Exelixis (EXEL) to $38 from $34 and keeps a Buy rating on the shares. The firm said they posted a ...

Net income for Q4 2024 increased by 63.7% to $139.9 million from $85.5 million in Q4 2023. Exelixis is targeting 2025 revenue of $2.15 billion to $2.25 billion. Exelixis reported increased revenue ...